The clinical manifestation of patients with pathogenic variants in POMK is rather broad (see introduction) and a varying spectrum of clinical manifestations and severity can even be observed within the subgroup of POMK-related WWS (classified as such by the authors/clinicians). This evidence concerns the gene POMK and muscular dystrophy-dystroglycanopathy, type A.